Neolina Pharmaceuticals

Neolina Pharmaceuticals is a preclinical-stage biotechnology company focused on the discovery and development of novel small molecule inhibitors targeting deubiquitinating enzymes (DUBs). The company's primary research efforts are centered on Ubiquitin Specific Peptidase 7 (USP7), a critical regulator of protein stability that influences key oncogenic and tumor-suppressive pathways. By selectively inhibiting USP7, Neolina aims to restore the function of p53 and other essential proteins to induce apoptosis in cancer cells. Based in San Diego, the company leverages deep expertise in the ubiquitin-proteasome system to address unmet needs in oncology. Neolina is currently advancing its lead programs through IND-enabling studies for the treatment of various solid and liquid tumors.